GLP-1 n.
The term GLP-1 refers to the natural hormone itself, not the longer-acting receptor agonist drugs like semaglutide or liraglutide that are modelled on it.
The definition
GLP-1 is the incretin hormone glucagon-like peptide-1, secreted by intestinal L-cells within minutes of eating. It stimulates glucose-dependent insulin release from the pancreas, slows gastric emptying, and signals satiety to appetite circuits in the brain. Receptor agonist drugs such as semaglutide mimic this pathway to treat type 2 diabetes and obesity.
The mechanism
GLP-1 belongs to the incretin hormone family: substances released by the gut after a meal that amplify the pancreas's own insulin response. Intestinal L-cells secrete the peptide within minutes of eating, and it was first isolated as a proglucagon-derived fragment shown to potently stimulate insulin release in the perfused pancreas 1. Beyond the pancreas, GLP-1 slows gastric emptying and suppresses glucagon, the paired mechanisms that underpin both its natural role in satiety and its use as a weight-loss therapy 3.
The hormone's reach extends to the brain: GLP-1 receptor activation modulates appetite- and reward-related regions, including the insula and amygdala, reducing the brain's response to food cues 2. Receptor agonist drugs such as semaglutide and liraglutide exploit this same satiety pathway as the natural hormone, and are now widely used for weight management and type 2 diabetes 34.
The distinction matters for how the terms get used. GLP-1 itself is the short-lived hormone circulating after a meal, produced continuously by L-cells throughout the gut. GLP-1 receptor agonist is the pharmacological class built to outlast and amplify that signal, not a synonym for the hormone itself 3.
In practice
Two colleagues order the same restaurant meal, but only one has been taking a GLP-1 receptor agonist for several weeks.
Worked example
One colleague finishes an identical plate within fifteen minutes and orders dessert. The other, on a GLP-1 receptor agonist, eats roughly half the meal, pauses for nearly an hour as the drug slows stomach emptying, and stops well before the plate is empty, reporting no hunger for the rest of the afternoon. Neither person is consciously restraining intake; the difference in behaviour traces directly to how strongly GLP-1 signalling is being amplified in each.
The gap illustrates why the drug class targets appetite regulation directly rather than requiring willpower at the table.
Why it matters
The stakes are substantial and increasingly well quantified. Across 47 randomised controlled trials, GLP-1 receptor agonists produced a mean extra weight reduction of 4.57 kg relative to comparators in people with overweight or obesity 4, an effect size that has made the drug class central to modern obesity treatment and pushed it well beyond its original diabetes indication. For anyone managing body composition or metabolic health, that magnitude of effect is no longer a marginal intervention; it rivals or exceeds what most lifestyle programmes achieve on their own.
That weight loss is not purely fat, however. A meaningful, variably reported proportion of it comes from lean mass, and the loss of muscle alongside fat has direct performance and metabolic consequences 5. This is why resistance training and adequate protein intake are increasingly built into treatment protocols rather than treated as optional extras alongside the medication.
Questions of record
What is GLP-1 and how does it work in the body?
GLP-1 is a hormone your gut releases after eating. It tells your pancreas to release insulin when blood sugar rises, slows how quickly your stomach empties, and signals your brain that you've had enough food, which is why it's central to natural appetite regulation.
Is GLP-1 the same thing as a GLP-1 receptor agonist drug like semaglutide?
No. GLP-1 is the natural hormone your body produces after eating. Semaglutide, liraglutide and similar receptor agonist drugs are synthetic molecules built to activate the same receptor pathway more persistently, which is part of why they can drive meaningful weight loss and are now widely used to treat obesity and type 2 diabetes.
Does GLP-1-driven weight loss cause muscle loss?
Some of it, yes, though the exact proportion is debated and varies across studies. Weight lost on GLP-1 receptor agonists includes a meaningful share of lean mass alongside fat, which is why clinicians increasingly pair these medications with resistance training and higher protein intake to protect muscle.
How much weight loss do GLP-1 receptor agonists typically produce?
Trial data put the effect at a mean extra 4.57 kg of weight loss compared with control across 47 randomised controlled trials in people with overweight or obesity. Individual results vary considerably depending on the specific drug, dose and how long someone stays on treatment.